Skip to search formSkip to main contentSkip to account menu

insulin aspart, insulin aspart protamine drug combination 30:70

Known as: BIAsp 30, biphasic insulin aspart 30:70, biphasic insulin aspart 30 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Aim: This 3-month study compared the effect on overall glycemic control of adding biphasic insulin aspart 30 (BIAsp30) and… 
2009
2007
2007
Aim:  To evaluate the efficacy and safety of adding biphasic insulin aspart 30 (BIAsp30; NovoMix® 30) to existing oral… 
2005
2005
OBJECTIVE Major advantages of modern insulin regimens containing premixed insulin analogues in comparison to traditional insulin… 
2005
2005
BACKGROUND Premixed insulin analogues reduce postprandial hyperglycemia in patients with Type 2 diabetes in comparison to… 
2005
2005
Aims  To compare pharmacokinetic characteristics of two biphasic insulin aspart (BIAsp) formulations: BIAsp30 and BIAsp70 (30… 
Highly Cited
2003
Highly Cited
2003
Objective:  Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine…